Glycyrrhizin has a high likelihood to be a victim of drug–drug interactions mediated by hepatic organic anion‐transporting polypeptide 1B1/1B3
- 16 June 2018
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (17) , 3486-3503
Abstract
Background and Purpose: Intravenous glycyrrhizin, having anti‐inflammatory and hepatoprotective properties, is incorporated into the management of liver diseases in China. This investigation was designed to elucidate the molecular mechanism underlying hepatobiliary excretion of glycyrrhizin and to investigate its potential for drug–drug interactions on organic anion‐transporting polypeptide (OATP)1B.Experimental Approach: Human transporters mediating hepatobiliary excretion of glycyrrhizin were characterized at the cellular and vesicular levels and compared with rat hepatic transporters. The role of Oatp1b2 in glycyrrhizin's elimination and pharmacokinetics was evaluated in rats using the inhibitor rifampin. A physiologically based pharmacokinetic (PBPK) model for glycyrrhizin, incorporating transporter‐mediated hepatobiliary excretion, was established and applied to predict potential drug–drug interactions related to glycyrrhizin in humans.Key Results: Hepatobiliary excretion of glycyrrhizin involved human OATP1B1/1B3 (Oatp1b2 in rats)‐mediated hepatic uptake from blood and human multidrug resistance‐associated protein (MRP)2/breast cancer resistance protein (ABCP)/bile salt export pump (BSEP)/multidrug resistance protein 1 (Mrp2/Abcp/Bsep in rats)‐mediated hepatic efflux into bile. In rats, rifampin impaired hepatic uptake of glycyrrhizin significantly increasing its systemic exposure. Glomerular‐filtration‐based renal excretion of glycyrrhizin was slow due to extensive protein binding in plasma. Quantitative analysis using the PBPK model demonstrated that OATP1B1/1B3 have critical roles in the pharmacokinetics of glycyrrhizin, which is highly likely to be a victim of drug–drug interactions when co‐administered with potent dual inhibitors of these transporters.Conclusions and Implications: Transporter‐mediated hepatobiliary excretion governs glycyrrhizin's elimination and pharmacokinetics. Understanding glycyrrhizin's potential drug–drug interactions on OATP1B1/1B3 should enhance the therapeutic outcome of glycyrrhizin‐containing drug combinations on liver diseases.Keywords
Funding Information
- National Natural Science Foundation of China (81603380)
This publication has 55 references indexed in Scilit:
- Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administrationBritish Journal of Pharmacology, 2013
- Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug InteractionsJournal of Medicinal Chemistry, 2012
- OATPs, OATs and OCTs: the organic anion and cation transporters of theSLCOandSLC22Agene superfamiliesBritish Journal of Pharmacology, 2012
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypesXenobiotica, 2010
- Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1Protein Science, 2009
- Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon‐resistant active chronic hepatitis CHepatology Research, 2007
- Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trialJournal of Hepatology, 2006
- Integration of Knowledge-Based Metabolic Predictions with Liquid Chromatography Data-Dependent Tandem Mass Spectrometry for Drug Metabolism Studies: Application to Studies on the Biotransformation of IndinavirAnalytical Chemistry, 2003
- Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic CyclingToxicology and Applied Pharmacology, 2000